519 reports of this reaction
2.8% of all THIOTEPA reports
#5 most reported adverse reaction
CYTOMEGALOVIRUS INFECTION is the #5 most commonly reported adverse reaction for THIOTEPA, manufactured by Amneal Pharmaceuticals LLC. There are 519 FDA adverse event reports linking THIOTEPA to CYTOMEGALOVIRUS INFECTION. This represents approximately 2.8% of all 18,516 adverse event reports for this drug.
Patients taking THIOTEPA who experience cytomegalovirus infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYTOMEGALOVIRUS INFECTION is a less commonly reported adverse event for THIOTEPA, but still significant enough to appear in the safety profile.
In addition to cytomegalovirus infection, the following adverse reactions have been reported for THIOTEPA:
The following drugs have also been linked to cytomegalovirus infection in FDA adverse event reports:
CYTOMEGALOVIRUS INFECTION has been reported as an adverse event in 519 FDA reports for THIOTEPA. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYTOMEGALOVIRUS INFECTION accounts for approximately 2.8% of all adverse event reports for THIOTEPA, making it a notable side effect.
If you experience cytomegalovirus infection while taking THIOTEPA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.